Use of dutasteride in carcinoma prostate

Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of urology 2014-01, Vol.30 (1), p.123-124
Main Author: Shrinivas, R
Format: Article
Language:English
Subjects:
Diagnosis
Drug therapy
Dutasteride
Health aspects
Medical research
Prostate cancer
Prostate-specific antigen
Radiation therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 124
container_issue 1
container_start_page 123
container_title Indian journal of urology
container_volume 30
creator Shrinivas, R
description Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate carcinoma (PCa) with curative intent, being randomized 1:1 between placebo and dutasteride 0.5 mg once daily for 2 year. Another significant finding noted was the lower incidence of disease progression in the dutasteride group (17%; 25 of 146) compared with the placebo (34%; 49 of 144) in terms of incidence of PSA related progression like PSADT < 3 mo, Absolute high PSA and clinical progression such as positive biopsy, bone metastasis and the need for rescue therapy like anti-androgens or luteinizing hormone-releasing hormone therapy.
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_006815eab5184ddf807c77f922653353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A364371148</galeid><doaj_id>oai_doaj_org_article_006815eab5184ddf807c77f922653353</doaj_id><sourcerecordid>A364371148</sourcerecordid><originalsourceid>FETCH-LOGICAL-d395r-ccf97894ad2c3da200266a7379c089f7485e5f455f668fd446b70030206a5b713</originalsourceid><addsrcrecordid>eNptkVtrGzEQhZfSQF03_2EhL3nZMLpLjyHkBoG-NM9irIuRs7tKpDUm_z4iTikFMwMDh28OM5xv3YoYowemKf_ercAoGIgw5Ef3s9YdACeaylV3-VxDn2Pv9wvWJZTkQ5_m3mFxac4T9q8l1wWX8Ks7izjWcP41193z3e2fm4fh6ff948310-CZEWVwLhqlDUdPHfNIAaiUqJgyDrSJimsRRORCRCl19JzLjQJgQEGi2CjC1t3j0ddn3NnXkiYs7zZjsp9CLluLZUluDBZAaiICbgTR3PuoQTmloqFUCsZar7uLo1d74m0f6mJ3eV_mdr4lgvCGgIF_1BabaZpjXgq6KVVnr5nkTBHCdaOGE9Q2zKHgmOcQU5P_469O8K18mJI7uQDHhUMeWxD1ZdwfQrFT8C9zPlhCmW1Z2Rzt36zYBw3Dkak</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1514353090</pqid></control><display><type>article</type><title>Use of dutasteride in carcinoma prostate</title><source>Medknow Open Access Medical Journals</source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Shrinivas, R</creator><creatorcontrib>Shrinivas, R</creatorcontrib><description>Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate carcinoma (PCa) with curative intent, being randomized 1:1 between placebo and dutasteride 0.5 mg once daily for 2 year. Another significant finding noted was the lower incidence of disease progression in the dutasteride group (17%; 25 of 146) compared with the placebo (34%; 49 of 144) in terms of incidence of PSA related progression like PSADT &lt; 3 mo, Absolute high PSA and clinical progression such as positive biopsy, bone metastasis and the need for rescue therapy like anti-androgens or luteinizing hormone-releasing hormone therapy.</description><identifier>ISSN: 0970-1591</identifier><identifier>EISSN: 1998-3824</identifier><language>eng</language><publisher>Vellore: Medknow Publications</publisher><subject>Diagnosis ; Drug therapy ; Dutasteride ; Health aspects ; Medical research ; Prostate cancer ; Prostate-specific antigen ; Radiation therapy</subject><ispartof>Indian journal of urology, 2014-01, Vol.30 (1), p.123-124</ispartof><rights>COPYRIGHT 2014 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Jan-Mar 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1514353090/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1514353090?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25731,27435,36989,44566,74869</link.rule.ids></links><search><creatorcontrib>Shrinivas, R</creatorcontrib><title>Use of dutasteride in carcinoma prostate</title><title>Indian journal of urology</title><description>Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate carcinoma (PCa) with curative intent, being randomized 1:1 between placebo and dutasteride 0.5 mg once daily for 2 year. Another significant finding noted was the lower incidence of disease progression in the dutasteride group (17%; 25 of 146) compared with the placebo (34%; 49 of 144) in terms of incidence of PSA related progression like PSADT &lt; 3 mo, Absolute high PSA and clinical progression such as positive biopsy, bone metastasis and the need for rescue therapy like anti-androgens or luteinizing hormone-releasing hormone therapy.</description><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Dutasteride</subject><subject>Health aspects</subject><subject>Medical research</subject><subject>Prostate cancer</subject><subject>Prostate-specific antigen</subject><subject>Radiation therapy</subject><issn>0970-1591</issn><issn>1998-3824</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkVtrGzEQhZfSQF03_2EhL3nZMLpLjyHkBoG-NM9irIuRs7tKpDUm_z4iTikFMwMDh28OM5xv3YoYowemKf_ercAoGIgw5Ef3s9YdACeaylV3-VxDn2Pv9wvWJZTkQ5_m3mFxac4T9q8l1wWX8Ks7izjWcP41193z3e2fm4fh6ff948310-CZEWVwLhqlDUdPHfNIAaiUqJgyDrSJimsRRORCRCl19JzLjQJgQEGi2CjC1t3j0ddn3NnXkiYs7zZjsp9CLluLZUluDBZAaiICbgTR3PuoQTmloqFUCsZar7uLo1d74m0f6mJ3eV_mdr4lgvCGgIF_1BabaZpjXgq6KVVnr5nkTBHCdaOGE9Q2zKHgmOcQU5P_469O8K18mJI7uQDHhUMeWxD1ZdwfQrFT8C9zPlhCmW1Z2Rzt36zYBw3Dkak</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Shrinivas, R</creator><general>Medknow Publications</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>DOA</scope></search><sort><creationdate>20140101</creationdate><title>Use of dutasteride in carcinoma prostate</title><author>Shrinivas, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d395r-ccf97894ad2c3da200266a7379c089f7485e5f455f668fd446b70030206a5b713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Dutasteride</topic><topic>Health aspects</topic><topic>Medical research</topic><topic>Prostate cancer</topic><topic>Prostate-specific antigen</topic><topic>Radiation therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shrinivas, R</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Indian journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shrinivas, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of dutasteride in carcinoma prostate</atitle><jtitle>Indian journal of urology</jtitle><date>2014-01-01</date><risdate>2014</risdate><volume>30</volume><issue>1</issue><spage>123</spage><epage>124</epage><pages>123-124</pages><issn>0970-1591</issn><eissn>1998-3824</eissn><abstract>Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate carcinoma (PCa) with curative intent, being randomized 1:1 between placebo and dutasteride 0.5 mg once daily for 2 year. Another significant finding noted was the lower incidence of disease progression in the dutasteride group (17%; 25 of 146) compared with the placebo (34%; 49 of 144) in terms of incidence of PSA related progression like PSADT &lt; 3 mo, Absolute high PSA and clinical progression such as positive biopsy, bone metastasis and the need for rescue therapy like anti-androgens or luteinizing hormone-releasing hormone therapy.</abstract><cop>Vellore</cop><pub>Medknow Publications</pub><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0970-1591
ispartof Indian journal of urology, 2014-01, Vol.30 (1), p.123-124
issn 0970-1591
1998-3824
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_006815eab5184ddf807c77f922653353
source Medknow Open Access Medical Journals; Publicly Available Content (ProQuest); PubMed Central
subjects Diagnosis
Drug therapy
Dutasteride
Health aspects
Medical research
Prostate cancer
Prostate-specific antigen
Radiation therapy
title Use of dutasteride in carcinoma prostate
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A03%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20dutasteride%20in%20carcinoma%20prostate&rft.jtitle=Indian%20journal%20of%20urology&rft.au=Shrinivas,%20R&rft.date=2014-01-01&rft.volume=30&rft.issue=1&rft.spage=123&rft.epage=124&rft.pages=123-124&rft.issn=0970-1591&rft.eissn=1998-3824&rft_id=info:doi/&rft_dat=%3Cgale_doaj_%3EA364371148%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d395r-ccf97894ad2c3da200266a7379c089f7485e5f455f668fd446b70030206a5b713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1514353090&rft_id=info:pmid/&rft_galeid=A364371148&rfr_iscdi=true